Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of LTG 001 for Acute Pain After Surgical Removal of Impacted Third Molars

NCT06774625 is registered in ClinicalTrials.gov with Latigo Biotherapeutics as lead sponsor.

NCT NCT06774625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06774625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of LTG 001 for Acute Pain After Surgical Removal of Impacted Third Molars
Lead sponsor
Latigo Biotherapeutics
Phase
Phase 2
Overall status
Completed
Start date
December 19, 2024
Completion date
August 8, 2025
Enrollment
250 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute pain, postoperative